Metropolitan Life Insurance CO Arcutis Biotherapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$3.25 - $11.77 $1,040 - $3,766	-320 Reduced 6.74%	4,431 $43,000
Q4 2023 Feb 14, 2024	BUY	$1.84 - $4.82 $3,554 - $9,312	1,932 Added 68.53%	4,751 $15,000
Q2 2023 Aug 10, 2023	BUY	$7.51 - $15.0 $7,983 - $15,945	1,063 Added 60.54%	2,819 $26,000
Q1 2023 May 15, 2023	SELL	$10.23 - $17.14 $7,263 - $12,169	-710 Reduced 28.79%	1,756 $19,000
Q4 2022 Jun 14, 2023	BUY	$13.96 - $20.4 $9,911 - $14,483	710 Added 40.43%	2,466 $36.5 Million
Q3 2022 Jun 14, 2023	BUY	$17.85 - $26.95 $12,673 - $19,134	710 Added 40.43%	2,466 $47.1 Million
Q3 2022 Mar 30, 2023	BUY	$17.85 - $26.95 $6,015 - $9,082	337 Added 15.83%	2,466 $47,000
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $6,015 - $9,082	337 Added 15.83%	2,466 $47,000
Q2 2022 Jun 20, 2023	BUY	$16.33 - $22.2 $6,091 - $8,280	373 Added 21.24%	2,129 $45,000
Q2 2022 Mar 30, 2023	BUY	$16.33 - $22.2 $6,923 - $9,412	424 Added 24.87%	2,129 $45,000
Q2 2022 Aug 11, 2022	BUY	$16.33 - $22.2 $6,923 - $9,412	424 Added 24.87%	2,129 $45,000
Q1 2022 Jun 20, 2023	SELL	$14.38 - $22.79 $733 - $1,162	-51 Reduced 2.9%	1,705 $32,000
Q1 2022 Mar 30, 2023	SELL	$14.38 - $22.79 $88,724 - $140,614	-6,170 Reduced 78.35%	1,705 $32,000
Q1 2022 May 12, 2022	SELL	$14.38 - $22.79 $88,724 - $140,614	-6,170 Reduced 78.35%	1,705 $33,000
Q4 2021 Jun 21, 2023	BUY	$14.98 - $25.5 $91,662 - $156,034	6,119 Added 348.46%	7,875 $163,000
Q3 2021 Jun 21, 2023	BUY	$19.28 - $27.1 $117,974 - $165,824	6,119 Added 348.46%	7,875 $188,000
Q2 2021 Jun 21, 2023	BUY	$24.42 - $34.75 $149,425 - $212,635	6,119 Added 348.46%	7,875 $214,000
Q2 2021 Mar 30, 2023	BUY	$24.42 - $34.75 $54,090 - $76,971	2,215 Added 39.13%	7,875 $214,000
Q2 2021 Aug 16, 2021	BUY	$24.42 - $34.75 $192,160 - $273,447	7,869 Added 131150.0%	7,875 $215,000
Q1 2021 Jun 26, 2023	BUY	$24.47 - $36.98 $95,530 - $144,369	3,904 Added 222.32%	5,660 $164 Million
Q1 2021 May 14, 2021	SELL	$24.47 - $36.98 $138,353 - $209,084	-5,654 Reduced 99.89%	6 $164,000
Q4 2020 Jun 22, 2023	BUY	$17.82 - $31.73 $69,569 - $123,873	3,904 Added 222.32%	5,660 $159,000
Q3 2020 Jun 26, 2023	BUY	$23.44 - $32.28 $91,509 - $126,021	3,904 Added 222.32%	5,660 $165,000
Q3 2020 Mar 30, 2023	BUY	$23.44 - $32.28 $44,137 - $60,783	1,883 Added 49.85%	5,660 $165,000
Q3 2020 Nov 13, 2020	BUY	$23.44 - $32.28 $44,137 - $60,783	1,883 Added 49.85%	5,660 $166,000
Q2 2020 Jun 26, 2023	BUY	$24.48 - $36.56 $49,474 - $73,887	2,021 Added 115.09%	3,777 $114,000
Q1 2020 Jul 12, 2023	BUY	$18.5 - $36.9 $37,388 - $74,574	2,021 Added 115.09%	3,777 $112,000
Q1 2020 Mar 30, 2023	BUY	$18.5 - $36.9 $24,253 - $48,375	1,311 Added 53.16%	3,777 $112,000
Q1 2020 May 15, 2020	BUY	$18.5 - $36.9 $69,874 - $139,371	3,777 New	3,777 $113,000

Others Institutions Holding ARQT

# of Institutions

197

Shares Held

129M

Call Options Held

738K

Put Options Held

82K

Jennison Associates LLC

11.7M
Shares

$108 Million
0.07% of portfolio
Rubric Capital Management LP New York, NY

11M
Shares

$102 Million
2.84% of portfolio
Suvretta Capital Management, LLC New York, NY

10.7M
Shares

$99.3 Million
3.92% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

8.79M
Shares

$81.4 Million
4.4% of portfolio
Black Rock Inc. New York, NY

8.62M
Shares

$79.8 Million
0.0% of portfolio

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $557M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account